Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOND: Sitagliptin vs Insulin vs Glimepiride in Newly Diagnosed T2DM
NCT03180281Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jul 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Fasting Blood Glucose at 3 months and Glycosylated Hemoglobin at 3 months. Status: unknown.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03180281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180281.